Cubit Diagnostics closes its latest SAFE financing round
CARLSBAD, Calif.--(BUSINESS WIRE)--Cubit Diagnostics today announced it has closed its latest round of SAFE (Simple Agreement for Future Equity) financing. The proceeds will fund the company's next phase of work, centered on locking in design freeze for its molecular CT/NG/TV assay and expanding its immunoassay program.
The company is on track and anticipates achieving design freeze of its CT/NG/TV molecular assay in Q4 2026, which sets up a clinical study in the first half of 2027. On the immunoassay side, the company has made meaningful progress to date and continues to hit key milestones across its initiatives.
The financing follows the recent strengthening of the company's board of directors, adding experienced leadership across diagnostics, regulatory, and commercial functions.
"We have the right team, a clear path forward, and the capital to achieve the next key milestones," said Kunal Sur, CEO of Cubit Diagnostics. "Getting to design freeze on CT/NG/TV this year and into a clinical study in 2027 is what this phase is about. We're also making real progress on the immunoassay side, which will give us the runway to expand the menu quickly."
"Putting molecular and immunoassay into one platform is novel and compelling, and we're incredibly excited about the progress we continue to make," added Kunal Sur. "Locking the CT/NG/TV design and getting into a clinical study next year is a key priority."
